莱茵生物(002166) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥252,624,843.19, a decrease of 10.55% compared to ¥282,409,086.05 in the same period last year[4] - Net profit attributable to shareholders for Q1 2023 was ¥19,937,378.89, down 48.11% from ¥38,424,186.65 in the previous year[4] - Basic and diluted earnings per share decreased by 57.14% to ¥0.03 from ¥0.07 in the same period last year[5] - Total operating revenue for Q1 2023 was ¥252,624,843.19, a decrease of 10.55% compared to ¥282,409,086.05 in the same period last year[33] - Net profit for Q1 2023 was ¥22,746,832.35, a decline of 43.1% from ¥39,987,940.47 in Q1 2022[34] - The company reported a total comprehensive income of CNY 13.31 million for Q1 2023, down from CNY 37.56 million in Q1 2022, representing a decrease of approximately 64.5%[35] Cash Flow and Investments - The net cash flow from operating activities was -¥552,283.38, a significant decline of 101.28% compared to ¥43,163,856.04 in Q1 2022[5] - Investment activities resulted in a net cash outflow of -¥90,049,150.51, a 262.24% increase in outflow compared to -¥24,858,973.21 in Q1 2022[15] - The company's cash and cash equivalents at the end of Q1 2023 were ¥542,250,586.83, down from ¥551,740,866.95 at the beginning of the year[28] - Cash inflow from financing activities was CNY 266.89 million in Q1 2023, slightly up from CNY 264.91 million in Q1 2022, indicating a marginal increase of about 0.7%[38] - The company incurred a total cash outflow from investing activities of approximately CNY 91.69 million in Q1 2023, compared to CNY 26.45 million in Q1 2022, reflecting an increase of about 246.5%[37] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥4,539,980,705.12, reflecting a 1.90% increase from ¥4,455,360,858.16 at the end of the previous year[5] - Total liabilities increased to ¥1,408,722,691.31 from ¥1,342,112,749.33, marking a rise of 4.3%[30] - Accounts receivable decreased to ¥236,155,952.46 from ¥337,100,542.93, indicating a reduction of approximately 30%[28] - Inventory increased to ¥1,103,569,076.12, up from ¥925,365,285.72, reflecting a growth of 19.3%[29] - The total equity attributable to shareholders of the parent company was ¥3,079,952,329.49, up from ¥3,064,759,634.69, reflecting a growth of 0.5%[31] Operational Highlights - The company reported a significant increase in construction in progress, rising 1155.16% to ¥25,644,380.82 due to ongoing projects[10] - The company experienced a 300.40% increase in contract liabilities, reaching ¥8,898,539.92, attributed to an increase in advance payments received[10] - The company reported a significant increase in R&D expenses, which rose to ¥11,642,233.61 from ¥9,354,723.77, an increase of 24.4%[34] - The company is advancing the construction of its stevia extraction factory and natural health product research institute, expected to commence production by the end of 2023[21] - The company is focusing on enhancing its competitive advantage through innovation in process research and development, technology transformation, and supply chain diversification[21] Shareholder Information - The top shareholder, Qin Benjun, holds 36.57% of the shares, amounting to 271,389,592 shares, with 129,200,000 shares pledged[18] - The company has raised a total of RMB 967.99 million through a private placement of 165,470,085 shares, with a net amount of RMB 961.11 million after expenses[25] Market and Product Insights - The company reported a significant impact on profits due to stable or slightly declining product prices amid high raw material costs for stevia and monk fruit[20] - The company is committed to maintaining a strong growth trajectory in the natural health products sector, driven by increasing consumer demand for natural and healthy products[21] - The company has completed 64.59% of the contract performance with Firmenich, totaling USD 22.28 million out of a contract amount of USD 34.5 million[23] - The company has a remaining procurement target amount of USD 12.22 million for 2023 under the contract with Firmenich, with a completion confidence for the remaining transaction volume[24]